unknown
Stage
2018
Founded
1
Investors
About
Acepodia is a clinical-stage biotechnology company developing first-in-class cell therapies using its unique Antibody-Cell Conjugation (ACC) platform technology to address gaps in cancer care. The company links tumor-targeting antibodies to proprietary immune cells, such as gamma delta T cells and off-the-shelf natural killer (NK) cells, to create novel antibody cell effector (ACE) therapies.
Explore Acepodia's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.